help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wieslander, E.
Right arrow Articles by Brattsand, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wieslander, E.
Right arrow Articles by Brattsand, R.

Am. J. Respir. Cell Mol. Biol., Volume 19, Number 3, September, 1998 477-484

Pharmacologic Importance of the Reversible Fatty Acid Conjugation of Budesonide Studied in a Rat Cell Line In Vitro

Elisabet Wieslander, E.-L. Delander, L. Järkelid, E. Hjertberg, A. Tunek, and R. Brattsand

Astra Draco AB, Preclinical Research and Development, Departments of Pharmacology and Kinetics and Metabolism, Lund, Sweden

Functional implications of the recently described fatty acid conjugation of budesonide (BUD) (Tunek, A., K. Sjödin, and G. Hallström, Drug Metabol. Dispos. 1997;25:1311-1317; Miller-Larson, A., E. Hjertberg, H. Mattsson, M. Dahlbäck, A. Tunek, and R. Brattsand, Am. J. Respir. Crit. Care Med. 1997;155:A353 [Abstr.]) were studied in a rat cell line, Rat1, transfected with the activation protein-1 (AP-1)-controlled regulatory element (TRE) driving the reporter gene beta -galactosidase. TRE is downregulated by glucocorticosteroids (GCS) through interaction with the AP-1 complex. BUD was compared to fluticasone propionate (FP), a potent glucocorticosteroid that does not form fatty acid conjugates. The kinetics and metabolism of the GCS were studied after incubation of either 3H-BUD or 3H-FP with transfected Rat1 cells. Up to 20% of added BUD was taken up into the cells over 24 h. The great majority of the intracellular radioactivity (80-90%) consisted of lipophilic BUD conjugates. After removing extracellular 3H-GCS, the outflow of radioactivity was studied. Only free BUD and not fatty acid conjugates was detected extracellularly, suggesting that hydrolysis of the conjugates was required to release BUD from the cell. During 165 min, less BUD (about 65% of totally incorporated) was released than FP (more than 90%). In the functional studies, FP was about six times more potent than BUD in downregulating TRE after 24 h continuous exposure. However, after a 6-h pulse of GCS, the effect of BUD persisted unchanged 18 h later, whereas FP had almost lost its efficacy (P < 0.05 between the drugs). In addition, the reversible conjugation process of BUD resulted in transferable GCS effects. Medium containing released BUD from previously loaded cells mediated nearly the same downregulatory effect after addition to naive cells as did continuous treatment. No such transferable effect was seen for FP. In conclusion, the reversible fatty acid conjugation of BUD resulted in prolonged cellular retention and anti-inflammatory activity after pulse exposure in this in vitro system. This fatty acid conjugation mechanism appears to add to the beneficial pharmacologic profile of BUD.




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
K. Lexmuller, H. Gullstrand, B.-O. Axelsson, P. Sjolin, S. H. Korn, D. S. Silberstein, and A. Miller-Larsson
Differences in Endogenous Esterification and Retention in the Rat Trachea between Budesonide and Ciclesonide Active Metabolite
Drug Metab. Dispos., October 1, 2007; 35(10): 1788 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. Winkler, G. Hochhaus, and H. Derendorf
How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids
Proceedings of the ATS, December 1, 2004; 1(4): 356 - 363.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. E. Wiley, M. Cwiartka, D. Alvarez, D. C. Mackenzie, J. R. Johnson, S. Goncharova, L. Lundblad, and M. Jordana
Transient Corticosteroid Treatment Permanently Amplifies the Th2 Response in a Murine Model of Asthma
J. Immunol., April 15, 2004; 172(8): 4995 - 5005.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Jendbro, C.-J. Johansson, P. Strandberg, H. Falk-Nilsson, and S. Edsbäcker
Pharmacokinetics of Budesonide and Its Major Ester Metabolite after Inhalation and Intravenous Administration of Budesonide in the Rat
Drug Metab. Dispos., April 13, 2001; 29(5): 769 - 776.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. MILLER-LARSSON, P. JANSSON, A. RUNSTROM, and R. BRATTSAND
Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1455 - 1461.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. JAFFUEL, P. DEMOLY, C. GOUGAT, P. BALAGUER, G. MAUTINO, P. GODARD, J. BOUSQUET, and M. MATHIEU
Transcriptional Potencies of Inhaled Glucocorticoids
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 57 - 63.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1998 American Thoracic Society. 		  ATS Best of the Web